ABVX

Abivax SA Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website abivax.com
Employees(FY) 26
ISIN US00370M1036

Performance

0.0%

-14.14%

-33.77%

-42.57%

-28.5%

YTD

-27.63%

Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Advanced Technical Analysis

Technical Analysis of ABVX 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong downward momentum, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 25 reinforces the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to b...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ABVX

Stock Rank

Recent News & Updates

2024-11-19 16:30
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq(GlobeNewswire)
2024-11-19 03:30
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq(Globenewswire)
2024-11-14 16:01
Abivax presents third quarter 2024 key financial information(GlobeNewswire)
2024-11-14 03:01
Abivax presents third quarter 2024 key financial information(Globenewswire)
2024-11-13 16:01
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax(GlobeNewswire)
2024-11-13 03:01
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax(Globenewswire)
2024-10-07 16:01
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation(GlobeNewswire)
2024-10-07 04:01
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation(Globenewswire)
2024-10-03 16:01
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease(GlobeNewswire)
2024-10-03 04:01
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease(Globenewswire)
2024-10-03 02:31
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance(GlobeNewswire)
2024-10-02 14:31
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance(Globenewswire)
2024-09-26 02:30
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024(GlobeNewswire)
2024-09-25 16:01
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model(GlobeNewswire)
2024-09-25 14:30
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024(Globenewswire)
2024-09-25 04:01
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model(Globenewswire)
2024-09-09 16:01
Abivax presents first-half 2024 financial results(GlobeNewswire)
2024-09-09 04:01
Abivax presents first-half 2024 financial results(Globenewswire)
2024-08-06 02:30
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone(GlobeNewswire)
2024-08-05 14:30
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone(Globenewswire)
2024-07-15 16:00
Abivax Provides Operational and Key Program Update(GlobeNewswire)
2024-07-15 04:00
Abivax Provides Operational and Key Program Update(Globenewswire)
2024-06-04 16:10
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting(GlobeNewswire)
2024-06-04 04:10
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting(Globenewswire)
2024-05-07 14:30
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024(Globenewswire)
2024-05-07 04:00
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents(Globenewswire)
2024-04-05 04:00
Abivax publishes financial reports with the French and U.S. securities regulatory agencies(Globenewswire)
2024-04-01 14:30
Abivax reports 2023 financial results and operational update(Globenewswire)
2024-02-13 02:50
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)(ACCESSWIRE)
2024-02-12 13:50
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)(Accesswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.